Sermorelin vs AOD 9604 compared: how each peptide works, studied doses, cycle length, side effects, and FDA status so you can weigh the research.
Sermorelin and AOD-9604 are not interchangeable peptides. Sermorelin is a growth hormone–releasing hormone (GHRH) analog that prompts the pituitary to release more growth hormone, while AOD-9604 is a synthetic fragment of human growth hormone studied for fat metabolism without raising GH or IGF-1. The sermorelin vs aod 9604 comparison therefore comes down to goal: GH-axis research on one side, fat-loss research on the other.
What sermorelin is and how it works
Sermorelin is a 29-amino-acid peptide that matches the first 29 amino acids of naturally occurring GHRH. It binds GHRH receptors in the pituitary and triggers pulsatile growth hormone release, which is why researchers study it in the context of age-related GH decline, sleep quality, and body composition.
- It acts upstream at the pituitary rather than supplying growth hormone directly.
- It can raise IGF-1 indirectly, because GH release stimulates IGF-1 production in the liver.
- Research protocols typically use subcutaneous injections at night to mimic the natural overnight GH pulse.
- Reported side effects include injection-site irritation, flushing, headache, and drowsiness.
Sermorelin acetate was once FDA-approved in the United States as a diagnostic agent sold under the brand name Geref. That product has been discontinued, and compounded sermorelin is not FDA-approved for human use.
What AOD-9604 is and how it works
AOD-9604 is a 16-amino-acid modified fragment of human growth hormone, corresponding to the region of the molecule (hGH 176–191) linked to fat metabolism. It was engineered to stimulate lipolysis and block lipogenesis without the growth-promoting or blood-sugar effects of full-length GH.
Human trials of AOD-9604 showed only modest reductions in body weight and fat mass, and development as an obesity drug was abandoned. Researchers still study the peptide because it does not appear to raise IGF-1 or worsen insulin sensitivity. AOD-9604 is not FDA-approved for any human use.
Sermorelin vs AOD-9604 at a glance
| Factor | Sermorelin | AOD-9604 |
|---|---|---|
| Peptide class | GHRH analog, 29 amino acids | hGH fragment 176–191, 16 amino acids |
| Primary mechanism | Stimulates pituitary growth hormone release | Stimulates lipolysis and inhibits fat storage |
| IGF-1 effect | Raises IGF-1 indirectly via GH | Little to no IGF-1 increase in studies |
| Blood sugar impact | Indirect through GH | No consistent effect reported |
| Common research route | Subcutaneous injection at bedtime | Subcutaneous injection, typically once daily |
| Studied outcomes | GH/IGF-1 levels, body composition, sleep | Modest body-fat reduction |
| FDA status | Discontinued as a diagnostic; compounded form not approved | Not approved for human use |
| Best-fit research goal | GH axis and recovery research | Fat metabolism research |
The half-life gap matters in practice. Sermorelin clears quickly and is usually timed to the body's overnight GH pulse, while AOD-9604 is far less time-sensitive in reported protocols.
Dosing and cycle length in published research
Sermorelin research protocols commonly report 100–300 mcg injected subcutaneously at bedtime, whereas AOD-9604 human trials used roughly 1 mg per day for about 12 weeks. Those figures come from study designs, not from approved prescribing information, and they are not medical advice.
Questions like how often do you take aod 9604 and what a reasonable aod 9604 cycle length should be usually trace back to that same small set of trials. Labels can add confusion too, since a vial labeled for aod-9604 5mg dosage contains 5 mg of lyophilized powder — many times a single research dose — and requires careful reconstitution math.
Handling is a common stumbling block. Complaints about aod-9604 gelling up typically come down to reconstitution technique, storage temperature, or shaking the vial; using bacteriostatic water, swirling gently, and refrigerating the solution are standard lab practices.
Safety, sourcing, and legal status
Both peptides are sold online, but the market is largely unregulated. Searching buy aod-9604 peptide in the United States turns up mostly "research use only" listings, which means the products have not been reviewed by the FDA for identity, purity, sterility, or human safety.
Standalone points worth remembering:
- Sermorelin and AOD-9604 act on different pathways and are not substitutes for each other.
- AOD-9604 is not FDA-approved for human use in the United States.
- Compounded sermorelin is not FDA-approved for human use in the United States.
- Research-grade peptides are not guaranteed to be sterile or accurately dosed.
Anyone considering either compound should discuss it with a licensed healthcare professional first, particularly people with a history of cancer, pituitary disorders, or diabetes.
Which peptide fits which research goal
Sermorelin is the relevant peptide when the question involves growth hormone output, IGF-1 levels, sleep architecture, or recovery markers. AOD-9604 is the one researchers reach for when the question is narrowly about fat metabolism without GH elevation.
People comparing aod 9604 vs mots-c are usually weighing a fat-metabolism fragment against a newer insulin-sensitizing peptide, and the two work through completely different mechanisms. Stacking sermorelin with AOD-9604 is sometimes discussed because their pathways do not directly overlap, but no clinical trial has tested the combination, and stacking raises the risk of unexpected side effects.
Frequently Asked Questions
Is sermorelin or AOD-9604 better for fat loss?
AOD-9604 was designed specifically to target fat metabolism, while sermorelin works indirectly by raising growth hormone and IGF-1. In human trials, AOD-9604 produced only modest fat loss and was never approved as an obesity treatment. Neither peptide is a proven weight-loss drug.
Does AOD-9604 have to be injected?
Most research protocols use once-daily subcutaneous injections of AOD-9604. Oral and topical versions have been studied, but absorption data are limited and inconsistent. Injecting any research peptide carries risks, including infection and dosing errors.
Can you stack sermorelin and AOD-9604?
Some users stack them because sermorelin targets the GH/IGF-1 axis and AOD-9604 targets fat metabolism. No published clinical trial has tested the combination, so the safety profile is unknown. A licensed healthcare professional should review any peptide use, especially with existing medical conditions.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.